266 related articles for article (PubMed ID: 19826249)
21. Enhanced anti-tumor effects of herpes simplex virus thymidine kinase/ganciclovir system by codelivering monocyte chemoattractant protein-1 in hepatocellular carcinoma.
Sakai Y; Kaneko S; Nakamoto Y; Kagaya T; Mukaida N; Kobayashi K
Cancer Gene Ther; 2001 Oct; 8(10):695-704. PubMed ID: 11687892
[TBL] [Abstract][Full Text] [Related]
22. Combinatory gene therapy with electrotransfer of midkine promoter-HSV-TK and interleukin-21.
Hanari N; Matsubara H; Hoshino I; Akutsu Y; Nishimori T; Murakami K; Sakata H; Miyazawa Y; Ochiai T
Anticancer Res; 2007; 27(4B):2305-10. PubMed ID: 17695518
[TBL] [Abstract][Full Text] [Related]
23. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma.
Kim SM; Lim JY; Park SI; Jeong CH; Oh JH; Jeong M; Oh W; Park SH; Sung YC; Jeun SS
Cancer Res; 2008 Dec; 68(23):9614-23. PubMed ID: 19047138
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of herpes simplex thymidine kinase mediated gene therapy in experimental pancreatic cancer.
Mäkinen K; Loimas S; Wahlfors J; Alhava E; Jänne J
J Gene Med; 2000; 2(5):361-7. PubMed ID: 11045430
[TBL] [Abstract][Full Text] [Related]
25. Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing.
Wiewrodt R; Amin K; Kiefer M; Jovanovic VP; Kapoor V; Force S; Chang M; Lanuti M; Black ME; Kaiser LR; Albelda SM
Cancer Gene Ther; 2003 May; 10(5):353-64. PubMed ID: 12719705
[TBL] [Abstract][Full Text] [Related]
26. Enhanced green fluorescent protein fusion proteins of herpes simplex virus type 1 thymidine kinase and cytochrome P450 4B1: applications for prodrug-activating gene therapy.
Steffens S; Frank S; Fischer U; Heuser C; Meyer KL; Dobberstein KU; Rainov NG; Kramm CM
Cancer Gene Ther; 2000 May; 7(5):806-12. PubMed ID: 10830728
[TBL] [Abstract][Full Text] [Related]
27. [Construction of a plasmid vector of fused protein genes driven by human insulin-like growth factor II P3 promoter].
Zhou HK; Yang DH; Tang SH; Huang W; Lu XH
Zhonghua Yi Xue Za Zhi; 2006 Jan; 86(2):106-10. PubMed ID: 16620715
[TBL] [Abstract][Full Text] [Related]
28. [Herpes simplex virus type 1 thymidine kinase/ganciclovir (HSV(1)-TK/GCV) system as an effective "in vivo death switch" of live tumor vaccines].
Kang Y; Xu CJ; Liu XS; Wu CQ; Zhong CP; Gu JR
Ai Zheng; 2005 Aug; 24(8):909-14. PubMed ID: 16086864
[TBL] [Abstract][Full Text] [Related]
29. Herpes simplex virus thymidine kinase/ganciclovir-mediated killing of tumor cell induces tumor-specific cytotoxic T cells in mice.
Yamamoto S; Suzuki S; Hoshino A; Akimoto M; Shimada T
Cancer Gene Ther; 1997; 4(2):91-6. PubMed ID: 9080117
[TBL] [Abstract][Full Text] [Related]
30. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters.
Majumdar AS; Hughes DE; Lichtsteiner SP; Wang Z; Lebkowski JS; Vasserot AP
Gene Ther; 2001 Apr; 8(7):568-78. PubMed ID: 11319624
[TBL] [Abstract][Full Text] [Related]
31. Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer.
Hall SJ; Sanford MA; Atkinson G; Chen SH
Cancer Res; 1998 Aug; 58(15):3221-5. PubMed ID: 9699645
[TBL] [Abstract][Full Text] [Related]
32. Suicide gene therapy of sarcoma cell lines using recombinant adeno-associated virus 2 vectors.
Veldwijk MR; Berlinghoff S; Laufs S; Hengge UR; Zeller WJ; Wenz F; Fruehauf S
Cancer Gene Ther; 2004 Aug; 11(8):577-84. PubMed ID: 15280909
[TBL] [Abstract][Full Text] [Related]
33. Mesenchymal stem cells contribute to the renal repair of acute tubular epithelial injury.
Herrera MB; Bussolati B; Bruno S; Fonsato V; Romanazzi GM; Camussi G
Int J Mol Med; 2004 Dec; 14(6):1035-41. PubMed ID: 15547670
[TBL] [Abstract][Full Text] [Related]
34. Tumor-specific transcriptional targeting of suicide gene therapy.
Qiao J; Doubrovin M; Sauter BV; Huang Y; Guo ZS; Balatoni J; Akhurst T; Blasberg RG; Tjuvajev JG; Chen SH; Woo SL
Gene Ther; 2002 Feb; 9(3):168-75. PubMed ID: 11859419
[TBL] [Abstract][Full Text] [Related]
35. Resistance developing after long-term ganciclovir prodrug treatment in a preclinical model of NSCLC.
Kurdow R; Schniewind B; Boehle AS; Haye S; Boenicke L; Dohrmann P; Kalthoff H
Anticancer Res; 2004; 24(2B):827-31. PubMed ID: 15161034
[TBL] [Abstract][Full Text] [Related]
36. [Construction and identification of recombinant vectors carrying herpes simplex virus thymidine kinase genes expressed in vascular endothelial cells].
Liu XP; Li BJ; Zhang C
Ai Zheng; 2006 Feb; 25(2):179-84. PubMed ID: 16480582
[TBL] [Abstract][Full Text] [Related]
37. Enhanced antitumor effects of a bicistronic adenovirus vector expressing both herpes simplex virus thymidine kinase and monocyte chemoattractant protein-1 against hepatocellular carcinoma.
Tsuchiyama T; Kaneko S; Nakamoto Y; Sakai Y; Honda M; Mukaida N; Kobayashi K
Cancer Gene Ther; 2003 Apr; 10(4):260-9. PubMed ID: 12679798
[TBL] [Abstract][Full Text] [Related]
38. Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm.
Rainov NG; Kramm CM; Aboody-Guterman K; Chase M; Ueki K; Louis DN; Harsh GR; Chiocca A; Breakefield XO
Cancer Gene Ther; 1996; 3(2):99-106. PubMed ID: 8729908
[TBL] [Abstract][Full Text] [Related]
39. Non-small cell lung cancer as a target disease for herpes simplex type 1 thymidine kinase-ganciclovir gene therapy.
Määttä AM; Tenhunen A; Pasanen T; Meriläinen O; Pellinen R; Mäkinen K; Alhava E; Wahlfors J
Int J Oncol; 2004 Apr; 24(4):943-9. PubMed ID: 15010834
[TBL] [Abstract][Full Text] [Related]
40. HSV-tk gene therapy for human renal cell carcinoma in nude mice.
Pulkkanen KJ; Parkkinen JJ; Laukkanen JM; Kettunen MI; Tyynela K; Kauppinen RA; Ala-Opas MY; Yla-Herttuala S
Cancer Gene Ther; 2001 Jul; 8(7):529-36. PubMed ID: 11498775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
